DexCom, Inc. Logo

DexCom, Inc.

DXCM

(2.2)
Stock Price

75,88 USD

10.01% ROA

29.58% ROE

41.56x PER

Market Cap.

27.822.475.610,00 USD

101.03% DER

0% Yield

16.95% NPM

DexCom, Inc. Stock Analysis

DexCom, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

DexCom, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (17.27%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 ROA

The stock's ROA (5.87%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

6 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (1.916) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (17.89x) suggests it's overvalued, potentially making it an expensive investment.

8 DER

The company has a high debt to equity ratio (117%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

DexCom, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

DexCom, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

DexCom, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

DexCom, Inc. Revenue
Year Revenue Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 2.169.790 100%
2007 4.627.000 53.11%
2008 9.838.000 52.97%
2009 29.693.000 66.87%
2010 48.631.000 38.94%
2011 76.266.000 36.24%
2012 99.900.000 23.66%
2013 160.000.000 37.56%
2014 259.200.000 38.27%
2015 402.000.000 35.52%
2016 573.300.000 29.88%
2017 718.500.000 20.21%
2018 1.031.600.000 30.35%
2019 1.476.000.000 30.11%
2020 1.926.700.000 23.39%
2021 2.448.500.000 21.31%
2022 2.909.800.000 15.85%
2023 3.900.000.000 25.39%
2023 3.622.300.000 -7.67%
2024 4.017.200.000 9.83%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

DexCom, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 2.902.000
2001 5.039.000 42.41%
2002 6.310.907 20.15%
2003 8.934.631 29.37%
2004 12.469.842 28.35%
2005 26.769.514 53.42%
2006 19.419.550 -37.85%
2007 16.131.000 -20.39%
2008 19.629.000 17.82%
2009 14.294.000 -37.32%
2010 23.227.000 38.46%
2011 30.747.000 24.46%
2012 39.500.000 22.16%
2013 44.800.000 11.83%
2014 69.400.000 35.45%
2015 137.500.000 49.53%
2016 156.100.000 11.92%
2017 185.400.000 15.8%
2018 417.400.000 55.58%
2019 273.500.000 -52.61%
2020 359.900.000 24.01%
2021 604.200.000 40.43%
2022 484.200.000 -24.78%
2023 525.600.000 7.88%
2023 505.800.000 -3.91%
2024 544.000.000 7.02%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

DexCom, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 21.111.000 100%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 194.000.000 100%
2016 274.300.000 29.27%
2017 327.300.000 16.19%
2018 408.800.000 19.94%
2019 482.600.000 15.29%
2020 544.200.000 11.32%
2021 684.100.000 20.45%
2022 867.200.000 21.11%
2023 0 0%
2023 1.004.600.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

DexCom, Inc. EBITDA
Year EBITDA Growth
2000 -4.014.000
2001 -6.724.000 40.3%
2002 -6.310.907 -6.55%
2003 -9.831.041 35.81%
2004 -13.131.623 25.13%
2005 -31.364.467 58.13%
2006 -46.622.126 32.73%
2007 -43.344.000 -7.56%
2008 -49.279.000 12.04%
2009 -43.460.000 -13.39%
2010 -34.426.000 -26.24%
2011 -41.085.000 16.21%
2012 -49.000.000 16.15%
2013 -21.900.000 -123.74%
2014 -21.500.000 -1.86%
2015 -57.100.000 62.35%
2016 -64.200.000 11.06%
2017 -35.800.000 -79.33%
2018 -103.800.000 65.51%
2019 164.500.000 163.1%
2020 382.700.000 57.02%
2021 277.400.000 -37.96%
2022 416.900.000 33.46%
2023 828.800.000 49.7%
2023 916.700.000 9.59%
2024 840.400.000 -9.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

DexCom, Inc. Gross Profit
Year Gross Profit Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 -8.789.163 100%
2007 -8.109.000 -8.39%
2008 -5.529.000 -46.66%
2009 3.661.000 251.02%
2010 18.443.000 80.15%
2011 35.844.000 48.55%
2012 46.600.000 23.08%
2013 100.100.000 53.45%
2014 176.300.000 43.22%
2015 278.400.000 36.67%
2016 378.400.000 26.43%
2017 492.100.000 23.11%
2018 663.900.000 25.88%
2019 931.500.000 28.73%
2020 1.280.100.000 27.23%
2021 1.680.500.000 23.83%
2022 1.883.100.000 10.76%
2023 2.493.200.000 24.47%
2023 2.288.900.000 -8.93%
2024 2.506.800.000 8.69%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

DexCom, Inc. Net Profit
Year Net Profit Growth
2000 -3.965.000
2001 -6.273.000 36.79%
2002 -7.708.029 18.62%
2003 -9.914.591 22.26%
2004 -13.946.464 28.91%
2005 -30.767.430 54.67%
2006 -46.599.291 33.97%
2007 -45.878.000 -1.57%
2008 -55.184.000 16.86%
2009 -53.524.000 -3.1%
2010 -55.170.000 2.98%
2011 -44.746.000 -23.3%
2012 -54.500.000 17.9%
2013 -29.800.000 -82.89%
2014 -22.400.000 -33.04%
2015 -57.600.000 61.11%
2016 -65.600.000 12.2%
2017 -50.200.000 -30.68%
2018 -127.100.000 60.5%
2019 101.100.000 225.72%
2020 493.600.000 79.52%
2021 154.700.000 -219.07%
2022 341.200.000 54.66%
2023 482.800.000 29.33%
2023 541.500.000 10.84%
2024 574.000.000 5.66%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

DexCom, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -1
2001 -1 0%
2002 -1 0%
2003 -1 100%
2004 -2 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 1 100%
2021 0 0%
2022 1 0%
2023 1 100%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

DexCom, Inc. Free Cashflow
Year Free Cashflow Growth
2003 -9.870.344
2004 -14.186.144 30.42%
2005 -27.230.391 47.9%
2006 -47.086.946 42.17%
2007 -36.650.000 -28.48%
2008 -39.943.000 8.24%
2009 -42.381.000 5.75%
2010 -49.536.000 14.44%
2011 -38.132.000 -29.91%
2012 -42.600.000 10.49%
2013 -5.500.000 -674.55%
2014 7.400.000 174.32%
2015 15.700.000 52.87%
2016 500.000 -3040%
2017 26.000.000 98.08%
2018 56.100.000 53.65%
2019 134.500.000 58.29%
2020 276.600.000 51.37%
2021 53.300.000 -418.95%
2022 304.700.000 82.51%
2023 511.900.000 40.48%
2023 218.800.000 -133.96%
2024 213.300.001 -2.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

DexCom, Inc. Operating Cashflow
Year Operating Cashflow Growth
2003 -9.461.735
2004 -12.428.621 23.87%
2005 -22.553.785 44.89%
2006 -43.734.840 48.43%
2007 -33.207.000 -31.7%
2008 -37.451.000 11.33%
2009 -39.389.000 4.92%
2010 -42.676.000 7.7%
2011 -30.126.000 -41.66%
2012 -33.100.000 8.98%
2013 2.400.000 1479.17%
2014 23.600.000 89.83%
2015 49.000.000 51.84%
2016 56.200.000 12.81%
2017 92.000.000 38.91%
2018 123.200.000 25.32%
2019 314.500.000 60.83%
2020 475.600.000 33.87%
2021 442.500.000 -7.48%
2022 669.500.000 33.91%
2023 748.500.000 10.55%
2023 269.200.000 -178.05%
2024 279.400.000 3.65%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

DexCom, Inc. Capital Expenditure
Year Capital Expenditure Growth
2003 408.609
2004 1.757.523 76.75%
2005 4.676.606 62.42%
2006 3.352.106 -39.51%
2007 3.443.000 2.64%
2008 2.492.000 -38.16%
2009 2.992.000 16.71%
2010 6.860.000 56.38%
2011 8.006.000 14.31%
2012 9.500.000 15.73%
2013 7.900.000 -20.25%
2014 16.200.000 51.23%
2015 33.300.000 51.35%
2016 55.700.000 40.22%
2017 66.000.000 15.61%
2018 67.100.000 1.64%
2019 180.000.000 62.72%
2020 199.000.000 9.55%
2021 389.200.000 48.87%
2022 364.800.000 -6.69%
2023 236.600.000 -54.18%
2023 50.400.000 -369.44%
2024 66.099.999 23.75%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

DexCom, Inc. Equity
Year Equity Growth
2000 -3.191.000
2001 -8.930.000 64.27%
2003 -32.600.852 72.61%
2004 -49.309.930 33.89%
2005 49.412.063 199.79%
2006 56.828.267 13.05%
2007 7.115.000 -698.71%
2008 -38.613.000 118.43%
2009 -18.445.000 -109.34%
2010 60.993.000 130.24%
2011 104.490.000 41.63%
2012 77.000.000 -35.7%
2013 84.100.000 8.44%
2014 140.200.000 40.01%
2015 221.200.000 36.62%
2016 283.800.000 22.06%
2017 419.400.000 32.33%
2018 663.300.000 36.77%
2019 882.600.000 24.85%
2020 1.826.500.000 51.68%
2021 2.251.500.000 18.88%
2022 2.131.800.000 -5.61%
2023 2.267.900.000 6%
2023 2.068.600.000 -9.63%
2024 2.434.300.000 15.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

DexCom, Inc. Assets
Year Assets Growth
2000 14.362.000
2001 8.640.000 -66.23%
2003 20.766.981 58.4%
2004 29.357.881 29.26%
2005 56.726.258 48.25%
2006 64.552.608 12.12%
2007 77.259.000 16.45%
2008 44.366.000 -74.14%
2009 46.948.000 5.5%
2010 77.164.000 39.16%
2011 120.475.000 35.95%
2012 106.000.000 -13.66%
2013 122.500.000 13.47%
2014 184.600.000 33.64%
2015 292.000.000 36.78%
2016 402.800.000 27.51%
2017 904.100.000 55.45%
2018 1.916.000.000 52.81%
2019 2.395.000.000 20%
2020 4.290.500.000 44.18%
2021 4.863.600.000 11.78%
2022 5.391.700.000 9.79%
2023 6.596.200.000 18.26%
2023 6.264.500.000 -5.29%
2024 6.799.200.000 7.86%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

DexCom, Inc. Liabilities
Year Liabilities Growth
2000 0
2001 0 0%
2003 53.367.833 100%
2004 78.667.811 32.16%
2005 7.314.195 -975.55%
2006 7.724.341 5.31%
2007 70.144.000 88.99%
2008 82.979.000 15.47%
2009 65.393.000 -26.89%
2010 16.171.000 -304.38%
2011 15.985.000 -1.16%
2012 29.000.000 44.88%
2013 38.400.000 24.48%
2014 44.400.000 13.51%
2015 70.800.000 37.29%
2016 119.000.000 40.5%
2017 484.700.000 75.45%
2018 1.252.700.000 61.31%
2019 1.512.400.000 17.17%
2020 2.464.000.000 38.62%
2021 2.612.100.000 5.67%
2022 3.259.900.000 19.87%
2023 4.328.300.000 24.68%
2023 4.195.900.000 -3.16%
2024 4.364.900.000 3.87%

DexCom, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.86
Net Income per Share
1.67
Price to Earning Ratio
41.56x
Price To Sales Ratio
7.07x
POCF Ratio
31.09
PFCF Ratio
41.81
Price to Book Ratio
11.39
EV to Sales
7.49
EV Over EBITDA
32.38
EV to Operating CashFlow
33.07
EV to FreeCashFlow
44.29
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
27,82 Bil.
Enterprise Value
29,48 Bil.
Graham Number
15.14
Graham NetNet
-0.53

Income Statement Metrics

Net Income per Share
1.67
Income Quality
1.34
ROE
0.3
Return On Assets
0.1
Return On Capital Employed
0.13
Net Income per EBT
0.83
EBT Per Ebit
1.18
Ebit per Revenue
0.17
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.14
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.63
Operating Profit Margin
0.17
Pretax Profit Margin
0.21
Net Profit Margin
0.17

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
2.23
Free CashFlow per Share
1.67
Capex to Operating CashFlow
0.25
Capex to Revenue
0.06
Capex to Depreciation
1.1
Return on Invested Capital
0.12
Return on Tangible Assets
0.1
Days Sales Outstanding
92.64
Days Payables Outstanding
76.42
Days of Inventory on Hand
141.96
Receivables Turnover
3.94
Payables Turnover
4.78
Inventory Turnover
2.57
Capex per Share
0.57

Balance Sheet

Cash per Share
7,82
Book Value per Share
6,10
Tangible Book Value per Share
5.75
Shareholders Equity per Share
6.1
Interest Debt per Share
6.21
Debt to Equity
1.01
Debt to Assets
0.36
Net Debt to EBITDA
1.82
Current Ratio
2.82
Tangible Asset Value
2,30 Bil.
Net Current Asset Value
0,48 Bil.
Invested Capital
4518300000
Working Capital
3,13 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,99 Bil.
Average Payables
0,29 Bil.
Average Inventory
579700000
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

DexCom, Inc. Dividends
Year Dividends Growth

DexCom, Inc. Profile

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

CEO
Mr. Kevin Ronald Sayer
Employee
9.500
Address
6340 Sequence Drive
San Diego, 92121

DexCom, Inc. Executives & BODs

DexCom, Inc. Executives & BODs
# Name Age
1 Ms. Leverne Marsh
Executive Vice President of Marketing
70
2 Mr. Michael Jon Brown
Executive Vice President & Chief Legal Officer
70
3 Mr. Sean Christensen
Director of Corporate Affairs & Head of Investor Relations
70
4 Stacey Stewart
Senior Vice President & Chief Information Officer
70
5 Mr. Girish Naganathan
Executive Vice President & Chief Technology Officer
70
6 Mr. Matthew Dolan
Executive Vice President of Strategy, Corporate Development & Dexcom Labs
70
7 Ms. Teri Lawver
Executive Vice President & Chief Commercial Officer
70
8 Mr. Kevin Ronald Sayer
Executive Chairman, Chief Executive Officer & President
70
9 Mr. Jacob Steven Leach
Executive Vice President & Chief Operating Officer
70
10 Mr. Jereme M. Sylvain
Executive Vice President, Chief Financial Officer & Chief Accounting Officer
70

DexCom, Inc. Competitors